Disruption of Retinol-Mediated IL-6 Expression in Colon Cancer-Associated Fibroblasts

Posted by

Oncotarget

Oncotarget published this trending research perspective on April 26, 2023 in Volume 14, entitled, “Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism" by researchers from Université de Poitiers, UMR CNRS 7267, Ecologie et Biologie des Interactions, France; Department of Medicine at Penn State Health Milton S. Hershey Medical Center, Hershey, PA; Department of Internal Medicine, Division of Gastroenterology and Hepatology, UTMB, Galveston, TX; Institute for Translational Sciences, UTMB, Galveston, TX; Department of Neuroscience and Cell Biology, UTMB, Galveston, TX. DOI - https://doi.org/10.18632/oncotarget.28399 Correspondence to - Iryna V. Pinchuk - ipinchuk@pennstatehealth.psu.edu Abstract Stromal myo-/fibroblasts (MFs) account for up to 30% of lamina propria cells in the normal human colon and their number is dramatically increased in colon cancer (CRC). Fibroblasts from cancers, also known as cancer-associated fibroblasts (CAFs), differ from normal colonic MF (N-MFs) and support tumor-promoting inflammation, in part due to increased IL-6 secretion. In this research perspective, we highlight recent data obtained regarding IL-6 regulation in colorectal cancer CAFs through vitamin A (retinol) metabolism, discuss current limitations in our understanding of the mechanisms leading to the CAF pro-inflammatory phenotype, and discuss potential approaches to target CAF retinoid metabolism during CRC treatment. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28399 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - tumor microenvironment, colon cancer, inflammation, fibroblasts, IL-6 About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957